• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gh Research Plc (NQ: GHRS )

    9.810 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 9.810
    Bid (Size) 7.250 (1)
    Ask (Size) 15.00 (1)
    Prev. Close 9.810
    Today's Range 9.810 - 9.810
    52wk Range 5.050 - 14.99
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates
    From GH Research PLC
    Via GlobeNewswire
    GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer
    From GH Research PLC
    Via GlobeNewswire

    Performance

    YTD
    +83.36%
    +83.36%
    1 Month
    -14.32%
    -14.32%
    3 Month
    -33.76%
    -33.76%
    6 Month
    +15.41%
    +15.41%
    1 Year
    -4.39%
    -4.39%

    More News

    Read More
    Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
    Via Talk Markets
    Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
    Via Talk Markets
    Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
    Via Talk Markets
    3 Psychedelic Stocks to Ride to the Moon and Beyond
    Via InvestorPlace
    Exposures Product Safety
    Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
    Via InvestorPlace
    Largest Clinical-Stage BioTech Drug Stocks Declined 6%
    Via Talk Markets
    Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
    Via Talk Markets
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
    Via Talk Markets
    Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
    Via Talk Markets
    Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
    Via Talk Markets
    GHRS Stock Earnings: GH Research Beats EPS for Q1 2024
    Via InvestorPlace
    GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
    From GH Research PLC
    Via GlobeNewswire
    Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
    Via Talk Markets
    Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
    Via Benzinga
    Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
    Via Talk Markets
    March Recap: Largest Psychedelic Drug Stocks Up Another 5%
    Via Talk Markets
    Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
    Via Benzinga
    Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
    Via Talk Markets
    Exposures Product Safety
    Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
    Via Benzinga
    Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
    Via Talk Markets
    GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.